DIM
SWTX

DC Investments Management’s SpringWorks Therapeutics SWTX Stock Holding History

DC Investments Management’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-26,513
Closed -$575K – 306
2019
Q3 		$575K Buy
+26,513
New +$627K 0.33% 82

Other funds holding SWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DC Investments Management's SWTX Position: Q4 2019 in Review

DC Investments Management sold out of SpringWorks Therapeutics (SWTX) in Q4 2019, closing a stake of 26,513 shares — an estimated $575K sold.

DC Investments Management first reported a position in SWTX in Q3 2019 and held it in 1 quarter. The position peaked at $575K in Q3 2019. 57 funds tracked by Wall St. Rank hold SWTX as of Q4 2019.

  • DC Investments Management reported no remaining SpringWorks Therapeutics position as of Q4 2019 after selling out during the quarter.
  • DC Investments Management sold 26,513 SpringWorks Therapeutics shares in Q4 2019, an estimated $575K.
  • DC Investments Management first reported a position in SpringWorks Therapeutics in Q3 2019 and held it in 1 quarter.
  • DC Investments Management's SpringWorks Therapeutics position peaked at $575K in Q3 2019.
  • 57 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q4 2019.

Based on DC Investments Management's 13F filing for Q4 2019, filed 7 Feb 2020.